Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
schizophrenia
Pharma
Teva's subdued outlook puts damper on strong 2024 results
Despite finishing strong in 2024, Teva’s cautious approach to the new year appears to have investors spooked.
Fraiser Kansteiner
Jan 29, 2025 1:13pm
Lyndra enlists Thermo Fisher for research, manufacturing support
Jan 15, 2025 3:36pm
J&J acquires CNS specialist Intra-Cellular for $14.6B
Jan 13, 2025 10:29am
Even through its remake, Alkermes retains upward trajectory: CEO
Jan 13, 2025 7:36am
BMS’ Cobenfy tipped to be top dog in growing schizophrenia space
Dec 19, 2024 9:17am
Intra-Cellular's unstoppable Caplyta nails another trial
Nov 5, 2024 10:15am
